RSS | Login | Register

DITROPAN XL

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare DITROPAN XL to:

Generic Name for DITROPAN XL

Oxybutynin chloride 5mg, 10mg, 15mg; ext-rel tabs.

Legal Classification:

Pharmacological Class for DITROPAN XL

Antispasmodic/anticholinergic.

Manufacturer of DITROPAN XL

Ortho-McNeil Pharmaceuticals, Inc.

Indications for DITROPAN XL

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Neurologic detrusor overactivity symptoms in children.

Adult dose for DITROPAN XL

Swallow whole. Take with fluid. Initially 5mg or 10mg once daily; may increase weekly in 5mg increments; max 30mg/day.

Children's dosing for DITROPAN XL

<6yrs: not recommended. ≥6yrs: Swallow whole. Take with fluid. Initially 5mg once daily; may increase in 5mg increments; max 20mg/day.

Contraindications for DITROPAN XL

Urinary or gastric retention; uncontrolled narrow-angle glaucoma; or patients at risk for these.

Warnings/Precautions for DITROPAN XL

Bladder outflow or GI obstruction. Hepatic or renal impairment. Ulcerative colitis. Intestinal atony. Myasthenia gravis. GERD. GI narrowing or stricture. Exposure to high environmental temperatures. Pregnancy (Cat.B). Nursing mothers.

Interactions for DITROPAN XL

Increased drowsiness with alcohol, other CNS depressants. Additive anticholinergic effects with other anticholinergics. May be potentiated by CYP3A4 inhibitors. Decreases GI motility, possibly affecting absorption of other drugs. Caution with drugs that can cause or exacerbate esophagitis (eg, bisphosphonates).

Adverse Reactions for DITROPAN XL

Dry mouth, constipation, somnolence, headache, diarrhea, nausea, tachycardia, blurred vision, dry eyes, other anticholinergic effects.

How is DITROPAN XL supplied?

Tabs—100

Related Disease:

Overactive bladder

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Phase 3 study of Anturol for the treatment of overactive bladder (OAB)

March 02, 2010

Antares Pharma announced that it has completed enrollment in the double-blind portion of their Phase 3 trial of Anturol (transdermal oxybutynin ATD gel) for the treatment of overactive bladder (OAB).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Gelnique gel available for overactive bladder (OAB)

May 21, 2009

Gelnique gel (oxybutynin chloride 10%) has been made available by Watson as a once-daily topical treatment for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

Phase 3 results of Gelnique for female overactive bladder

April 28, 2009

Watson Pharmaceuticals announced results of its Phase 3 study of Gelnique (oxybutynin chloride) 10% gel for the treatment of women with overactive bladder (OAB) and urinary urge incontinence.